AbCellera Biologics (ABCL) Accumulated Depreciation & Amortization (2020 - 2025)
AbCellera Biologics (ABCL) has disclosed Accumulated Depreciation & Amortization for 6 consecutive years, with $5.2 million as the latest value for Q3 2025.
- For the quarter ending Q3 2025, Accumulated Depreciation & Amortization fell 85.79% year-over-year to $5.2 million, compared with a TTM value of $5.2 million through Sep 2025, down 85.79%, and an annual FY2024 reading of $39.7 million, up 62.81% over the prior year.
- Accumulated Depreciation & Amortization was $5.2 million for Q3 2025 at AbCellera Biologics, down from $10.8 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $41.4 million in Q2 2024 and bottomed at $4.8 million in Q1 2024.
- Average Accumulated Depreciation & Amortization over 5 years is $18.6 million, with a median of $14.5 million recorded in 2021.
- The sharpest move saw Accumulated Depreciation & Amortization skyrocketed 158.7% in 2021, then crashed 85.79% in 2025.
- Year by year, Accumulated Depreciation & Amortization stood at $14.5 million in 2021, then soared by 92.67% to $27.8 million in 2022, then fell by 12.38% to $24.4 million in 2023, then skyrocketed by 62.81% to $39.7 million in 2024, then crashed by 86.79% to $5.2 million in 2025.
- Business Quant data shows Accumulated Depreciation & Amortization for ABCL at $5.2 million in Q3 2025, $10.8 million in Q2 2025, and $5.3 million in Q1 2025.